FDA
-
-
-
-
-
-
-
Tempus Reports Third Quarter 2025 Results
-
-
-
-
-
-
-
Tempus AI Inc (TEM) PT Raised to $98 at H.C. Wainwright
-
-
-
-
-
-
-
Tempus AI (TEM) Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
-
-
-
-
-
-
-
Tempus Reports Fourth Quarter and Full Year 2024 Results
-
-
-
-
-
-
-
Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That’s Expected to be a $7.2 Billion Market by 2029
-
-
-
-
-
-
-
Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-AF, an AI-based Algorithm that Identifies Patients at Increased Risk of AFib
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

